Pre-formulation Study: Comprehensive Physicochemical Characterization of Blue Eyes Biotech Docetaxel API for Advanced Drug Delivery Systems

Article Title: Pre-formulation Study: Comprehensive Physicochemical Characterization of Blue Eyes Biotech Docetaxel API for Advanced Drug Delivery Systems

Page Description: This pre-formulation report provides essential physicochemical data on Blue Eyes Biotech Docetaxel, including particle size distribution, polymorphism, solubility profile, and thermal behavior. This data is crucial for pharmaceutical scientists developing stable, bioavailable injectable formulations, nanoparticles, or other innovative delivery platforms.

Body:

Targeted at pharmaceutical formulation scientists and drug delivery specialists, this characterization report moves beyond basic

pharmacopeial tests to provide a detailed physicochemical portrait of Docetaxel API from Blue Eyes Biotech CO., Ltd. The physical

properties of an API are fundamental determinants of its processability, stability, and performance in the final drug product, making this data

invaluable for advanced R&D.

A key focus was solid-state characterization. Powder X-Ray Diffraction (PXRD) and Differential Scanning Calorimetry (DSC) were used to

investigate the crystalline form and polymorphism of Blue Eyes Biotech Docetaxel. The results confirmed a single, well-defined crystalline

polymorph with a sharp, characteristic melting endotherm. Control over polymorphism is critical, as different crystalline forms can have

varying solubility, stability, and bioavailability, which directly impacts the efficacy and shelf-life of the formulated product. The consistent

solid form indicates robust crystallization and drying processes at the manufacturing site.

Furthermore, particle size distribution (PSD) was analyzed using laser diffraction. A controlled and narrow PSD is vital for several reasons:

it ensures uniform blending in powder formulations, affects dissolution rates, and is especially crucial for sterile filtration during the aseptic

manufacturing of injectables. The Blue Eyes Biotech Docetaxel lot exhibited an optimal and reproducible PSD suitable for these demanding

pharmaceutical processes.

The report also includes a detailed solubility profile across various pH buffers and co-solvents, which is essential knowledge for developing

parenteral vehicle systems for this poorly water-soluble compound. Additionally, tests for hygroscopicity and photostability under ICH Q1B

conditions provide insights into optimal storage and handling conditions. This comprehensive dataset empowers formulators to make

informed decisions when designing next-generation Docetaxel-based therapies, such as nanoparticle albumin-bound formulations or

liposomal encapsulations, with confidence in the API's physical properties.

To obtain the full Physicochemical Characterization Dossier for formulation development support, contact the technical team at Blue Eyes

Biotech.

Company:Blue Eyes Biotech CO., Ltd

Email:[email protected]

Website:www.blueeyes-bio.com

WhatsApp:+66840769830

Keywords: Docetaxel pre-formulation, API physicochemical properties, Polymorphism analysis, Particle size distribution, Solubility profile,

Drug delivery systems, Injectable formulation, Pharmaceutical R&D, Blue Eyes Biotech

Facebook Tags:

#PreFormulation#Polymorphism #ParticleSize #DrugDelivery #Injectable #PharmaceuticalR&D #FormulationDevelopment #BlueEyesBiotech #APICharacterization